Participant :

Lab code :

METHOD DESCRIPTION

SCREENING ANALYSIS

(short description of the screening method / equipment)

**Sample preparation:**

**Sample amount:** ……. mL/mg of urine sample

**Hydrolysis:** yes  no  if yes: glucoronidase/sulfatase

protease

mineralic acid

other ………………………..

**Clean-up:** liquid/liquid  solvent: ........................................... SPE  phase: ............. solvent: ...................

QuECHERS

other: ........................................................................

**Derivatisation:**  yes  if yes - reagent: ............................................

no:

**Measurement method:** LC  column: .........................................................

temperature programme:...............................

eluent: ...........................................................

gradient:.........................................................

.........................................................

flow rate::......................................................

column temperature:......................................

injection volume:...........................................

ELISA

Biosensor

Test-Kit

other: ............................

**Detection method:** MS   equipment: ........................................

Ion trap:

Triple quad:

TOF / QTOF:

Orbitrap:

FLU

DAD

UV

other: …………………………................................

**MS/MS conditions (diagnostic ions):**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Analyte** | **Precursor Ion** | **Product Ions** | | | **IS** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| **Internal Standards** |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |

**Source of Standards: ..……………………………………………………………………..**

**………………………………………………………………………**

**………………………………………………………………………**

**………………………………………………………………………**

**………………………………………………………………………**

**………………………………………………………………………**

**………………………………………………………………………**

**Calibration:** External calibration (solvent)

single-level:

multi-level:

Matrix calibration

single-level:

multi-level:

Calibration with IS

Standard addition

**Additional remarks:** ………………………………………………………………………….

………………………………………………………………………..

………………………………………………………………………..

………………………………………………………………………..

………………………………………………………………………..

………………………………………………………………………..

**Reference (method):** ………………………………………………………………………….

Which analytes can be detected with this screening method? What is the CCβscreening for these analytes in this matrix?

|  |  |  |
| --- | --- | --- |
| **Analyte** | **Measurement and detection method** | **CCβscreening\* in egg (µg/kg)** |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |

**\*Please indicate the values for all individual substances.**

Remarks: *If data concerning the CCβ screening cannot be entered yet, please indicate the limit of quantification and limit of*

*determination or similar limits and the type of determination. Please mark entries correspondingly.*

***If several methods were used for the screening analysis, please copy pages1 to 6 and fill them in***

***separetely for each method.***

Participant :

Lab code :

RESULT FORM

SCREENING ANALYSIS

The screening results of the above-mentioned sample were positive for the following coccidiostats:

*(Please note that only one sample preparation per sample was required. If parallel analyses were performed, please enter* ***each individual result****,* ***do not enter means****!)*

***Sample code: ..................***

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Detected**  **analytes** | **Nature of screening result**  **(please tick)** | | | **Concentration**  **(single values)**  **(ng/mL urine)** |
| estimated | semi-quantitative | quantitative |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |

The presence of β-agonists in the above mentioned sample is not indicated by the screening results:

Remarks: .....................................................................................................................................

***Sample code: ................***

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Detected**  **analytes** | **Nature of screening result**  **(please tick)** | | | **Concentration**  **(single values)**  **(ng/mL urine)**  estimated |
| estimated | semi-quantitative | quantitative |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |

The presence of β-agonists in the above mentioned sample is not indicated by the screening results:

Remarks: .....................................................................................................................................

***Sample code: ................***

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Detected**  **analytes** | **Nature of screening result**  **(please tick)** | | | **Concentration**  **(single values)**  **(ng/mL urine)**  estimated |
| estimated | semi-quantitative | quantitative |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |

The presence of β-agonists in the above mentioned sample is not indicated by the screening results:

Remarks: .....................................................................................................................................

***Sample code: ..............***

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Detected**  **analytes** | **Nature of screening result**  **(please tick)** | | | **Concentration**  **(single values)**  **(ng/mL urine)**  estimated |
| estimated | semi-quantitative | quantitative |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |

The presence of β-agonists in the above mentioned sample is not indicated by the screening results:

Remarks: .....................................................................................................................................

**How do you confirm a positive screening result?**

**Method: …………………………………………………………**

**Laboratory: …………………………………………………………**